Lixte Biotechnology Holdings, Inc. (LIXT: OTCQB) | Lixte Biotechnology’s LB-100 to be Evaluated by the National Cancer Institute in a Clinical Study of LB-100’s Ability to Enter Recurrent Glioblastoma Multiforme Brain Tumors

OTC Markets Group – News, Filings & Corporate Actions

Pin It